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Abstract
The presence of SF3B1 gene mutations is a hallmark of refractory anemia with ring sidero-
blasts (RARS). However, the mechanisms responsible for iron accumulation that character-
ize the Myelodysplastic Syndrome with ring sideroblasts (MDS-RS) are not completely
understood. In order to gain insight in the molecular basis of MDS-RS, an integrative study
of the expression and mutational status of genes related to iron and mitochondrial metabo-
lism was carried out. A total of 231 low-risk MDS patients and 81 controls were studied.
Gene expression analysis revealed that iron metabolism and mitochondrial function had the
highest number of genes deregulated in RARS patients compared to controls and the re-
fractory cytopenias with unilineage dysplasia (RCUD). Thus mitochondrial transporters
SLC25 (SLC25A37 and SLC25A38) and ALAD genes were over-expressed in RARS.
Moreover, significant differences were observed between patients with SF3B1mutations
and patients without the mutations. The deregulation of genes involved in iron and mito-
chondrial metabolism provides new insights in our knowledge of MDS-RS. New variants
that could be involved in the pathogenesis of these diseases have been identified.
Introduction
Myelodysplastic syndromes (MDS) are clonal hematological disorders characterized by blood
cytopenias, ineffective hematopoiesis and hypercellular bone marrow [1]. According to the
WHO classification (2008), six subtypes of MDS are distinguished: refractory cytopenia with
unilineage dysplasia (RCUD), refractory anemia with ring sideroblasts (RARS), refractory cyto-
penia with multilineage dysplasia (RCMD), refractory anemia with excess blasts (RAEB-1 and
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RAEB-2), MDS-unclassified (MDS-U) and MDS associated with isolated del(5q) [2]. Patients
with RARS present with isolated anemia, hypochromic erythrocytes, hyperplastic ineffective
erythropoiesis and mitochondrial ferritin accumulation in erythroid precursor cells. RARS and
RCMD with ring sideroblasts (RCMD-RS) are defined by the presence of more than 15%
ringed sideroblasts. The accumulation of ferritin is present in the ring sideroblasts and this is
likely to be involved in the increased apoptosis of erythroblasts and, therefore, in ineffective
erythropoiesis [3].
Iron is essential for heme synthesis and Fe-S cluster biogenesis in the erythroid cell. Iron is
acquired by the erythroid precursors and it is imported into mitochondria by SLC25A37
(Mitoferrin-1) [4]. This protein is a member of the solute carrier family, and is localized in the
inner mitochondrial membrane, where it is an essential iron importer. Heme synthesis is initi-
ated in the mitochondrion and the iron that is not incorporated during this process is stored in
Fe-S clusters and transported out of the mitochondrion by the ABCB7 membrane protein
[5,6,7].
High expression of some heme biosynthesis-related genes, such as ALAS2 and FECH, have
been seen in RARS patients [8], whilst low levels of ABCB7 gene expression in patients with
RARS compared with other MDS subtypes have also been found [9]. However, no mutations
in these genes have been detected in acquired RARS [9,10]. By contrast, several genetic lesions
have been identified in inherited sideroblastic anemias, including mutations in the SLC25A38,
ALAS2 and ABCB7 genes [11,12,13,14,15].
The presence of recurrent somatic mutations of the splicing factor 3B subunit 1 (SF3B1)
gene in a high proportion of patients with RARS (64–83%) or RCMD-RS (57–76%) have been
recently demonstrated [16,17,18,19,20,21]. SF3B1 is located on chromosome 2q33.1 and en-
codes the SF3B1 protein, which plays a role in pre-mRNA splicing and associated transcription
[21]. In addition, recent studies have shown a possible role of SF3B1 in the formation of ring
sideroblasts in MDS [22,23]. However, some authors suggest that RARS is a disease resulting
from a specific alteration in one or more genes involved in mitochondrial function, iron distri-
bution, or both [3]. Thereby, the abnormal mitochondrial iron metabolism that characterizes
RARS is not completely understood and the pathogenesis of ring sideroblasts in MDS remains
to be clarified.
In order to gain insight in our knowledge of the abnormal iron accumulation, defective mi-
tochondrial function and ineffective heme biosynthesis in low-risk MDS, an integrative study
of both expression and mutational status of genes related to iron and mitochondria was carried
out. Our study has shown that SLC25A37 and SLC25A38 were over-expressed in RARS pa-
tients, and has identified one sequence change in the ALAD gene that could contribute to a bet-
ter understanding of the pathogenesis of sideroblastic MDS.
Materials and Methods
Patients, samples and cell separation
A total cohort of 231 low-risk MDS patients and 81 controls were included in the studies per-
formed in this work. 69 low-risk MDS patients (30 RARS patients and 39 RCUD patients) and
31 controls without hematological malignancies were included in the gene expression profiling
study. Moreover, 6 MDS with ring sideroblasts were analyzed by massive DNA-sequencing
techniques, while 175 low-risk MDS patients were analyzed by conventional Sanger sequencing
(100 MDS with ring sideroblasts and 75 were other low-risk MDS) (S1 Table). All patients
were classified according to the World Health Organization (WHO) 2008 criteria [2] (with
the exception of RCMD-RS, which we maintain from the World Health Organization, 2002
[24] as a separate category). In addition, 50 healthy controls were also included in the Sanger
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sequencing study. Mononuclear cells were isolated from bone marrow (BM) of MDS patients
and controls by density gradient (Ficoll). The unfractionated mononuclear cells were used for
the expression and sequencing studies. In addition, CD3+ cells from peripheral blood from pa-
tients of interest were purified using magnetically activated cell sorting (MACS) CD3 MicroBe-
ads (Miltenyi Biotec, Bergisch Gladbach, Germany). The study was approved by the Local
Ethical Committee “Comité Ético de Investigación Clínica, Hospital Universitario de Sala-
manca” and written informed consent was obtained from each patient and their relatives.
RNA and DNA isolation
Total RNA was extracted from cells by homogenization in TRIZOL (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s protocol, treated with RQ1 RNAse-Free DNase (Promega,
Madison, USA) to eliminate genomic DNA contamination, and finally purified with RNeasy
Minikit (Qiagen, Hilden, Germany). RNA quantity and quality was determined with an Agilent
2100 Bioanalyzer (Santa Clara, CA, USA). Genomic DNA from subject samples was isolated
using DNeasy blood and tissue kit following the manufacturer’s protocol (Qiagen).
Gene expression microarray studies
Gene expression profiling (GEP) studies were carried out as part of the Microarray Innovations
in LEukemia (MILE) study [25]. GeneChip Human Genome U133 plus 2.0 arrays (Affymetrix,
High Wycombe, UK) are gene expression arrays containing 54 613 oligonucleotide probesets
that map onto 18 950 human gene loci (obtained using the mapping of microarrays probes to
ENSEMBL gene IDs provided by GATExplorer) [26]. RNA was labeled and hybridized accord-
ing to protocols from Affymetrix. Briefly, 100 ng of total RNA was amplified and labeled using
the GeneChip two-cycle cDNA synthesis kit and GeneChip IVT labeling kit (Affymetrix Inc.)
and then hybridized onto a Human Genome U133 Plus 2.0 microarray, after quality checking
on GeneChip Test3 arrays. Washing and scanning were done with a Fluidics Station 400 and
GeneChip Scanner (Affymetrix Inc.) as previously described [27]
Bioinformatic methods for global expression profiling and differential analysis. Robust
Microarray Analysis (RMA) algorithm was applied to the raw data of the expression arrays to
achieve background correction and intra- and inter-normalization, and to calculate the expres-
sion signal [28]. The Significant Analysis of Microarrays (SAM) algorithm was used to identify
genes with statistically significant changes differences in expression between different classes
[29]. For this purpose, samples were permuted over 100 cycles by using the two-class (un-
paired) and multiclass response format, assuming unequal variances for the genes. Significant
genes were selected on the basis of a false discovery rate (FDR) of<0.05. To select each gene
the p-values of each statistical test were transformed to q-values using the indicated FDR
threshold. The algorithms described were applied using the R programming environment and
the Bioconductor package.
Validation of the gene expression signature with independent cohort of patients. In
order to validate the gene expression signatures obtained with the MDS patient cohorts stud-
ied, an independent analysis was performed using gene expression data from bone marrow
CD34+ cells of MDS patients and healthy controls obtained from GSE19429 (GEO database:
http://www.ncbi.nlm.nih.gov/geo/).
Differential analysis in low-risk MDS with and without SF3B1/SRSF2mutations. In
order to find genes that mark possible differences between low-risk MDS samples with mutated
SF3B1/SRSF2 genes (n = 22) and low-risk MDS samples without mutations (n = 13), a recursive
algorithm written in R was designed and applied. This alogarithm produces multiple subsets of
samples from each class and run differential expression analysis for each one of these subsets
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using LIMMA [30]. In this way, random selected groups of 7 versus 7 samples were analyzed
running a total of 10000 differential expression tests. The recursive algorithm identified and
counted the genes that gave a significant differential expression in each one of the contrasts
(using as cutoff: q-value< 0.01, that corresponds to the p-value adjusted by FDR). In this way,
a gene signature of 200-top genes was selected. Once these genes were selected we used an out-
come/response algorithm called Global Test [31] to check further if the genes selected were
able to predict the two classes investigated.
The same strategy was used to compare MDS-RS with mutated SF3B1 (n = 13) and non-
mutated SF3B1 (n = 6). However in this case, we random selected groups of 4 versus 4 samples
running a total of 7425 differential expression analyses and a p-value adjusted by FDR< 0.10
was used. A gene signature of 75-top genes was selected, being genes that appeared as signifi-
cant in at least ten different contrasts.
Functional enrichment analysis. To analyze the functional enrichment of the selected
gene lists the bioinformatic resource DAVID (http://david.abcc.ncifcrf.gov/) [32] and the web-
delivered bioinformatics tool set IPA (Ingenuity Pathway Analysis 9.0; http://www.ingenuity.
com) were used. Both tools enable the functional modules and the most relevant biological pro-
cesses present in the gene lists to be identified by statistical enrichment analysis based on
contingency tests.
Targeted Sequence Capture and DNA Sequencing assay
Array-based sequence capture (Roche NimbleGen) followed by next-generation sequencing
(Roche GS FLX Titanium sequencing platform) was used to analyze 93 genes related to hema-
tological malignancies. Details of the design of the array, 454 sequencing, coverage statistics
and data analysis are provided in the Supplementary Methods (S1 Methods).
Real-Time PCR
The expression levels of selected genes were analyzed by Real-Time PCR. First-strand cDNA
was generated from 1 μg of total RNA using poly-dT as primer and the M-MLV reverse tran-
scriptase (Promega). Real-time PCR was performed in triplicate and was analyzed as previously
described [33]. The primers were designed for specific sequences (S2 Table) and checked by
the BLAST algorithm [34].
Sanger sequencing
To elucidate and validate the presence of possible genes variations, Sanger re-sequencing was
carried out. Oligonucleotide primers were designed against all exons of SLC25A37 and a geno-
mic fragment of exons 6 and 7 in the ALAD gene. A pair of primers to amplify a 1 696-bp geno-
mic fragment and a second reverse internal primer for the sequencing in ALAD was used.
All primers were designed using Primer3 (http:/frodo.wi.mit.edu/primer3/) (S3 Table). In
addition, the previously published primers against the exons more frequently mutated of
SLC25A38 in congenital sideroblastic anemia [14] and against the exon 14 and 15 of SF3B1
were used [17]. Genomic DNA was amplified with the Fast Start High Fidelity PCR System
(Roche, Basel, Switzerland) following the manufacturer’s instructions and including some vari-
ations of the annealing temperature and magnesium concentration (S3 Table). DNA sequences
were evaluated using Scanner v1.0 (Applied Biosystems, Carlsbad, CA, USA) and Accelrys DS
Gene v1.5 software. Data were analysed using annotations of genome version GRCh37 (hg19).
Bioinformatics analysis of missense variants. The effects of amino acid changes on pro-
tein function were predicted with SIFT using the protein sequences of human ALAD as the
DNA Variants in Refractory Anemia with Ring Sideroblasts
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input. Homologous protein sequences of the human ALAD gene were retrieved from the NCBI
genome database with BLASTP.
Results
Gene expression analysis reveals an iron-related profile in RARS
patients
The gene expression profile (GEP) from the BM of 30 RARS patients was compared with that
of 31 healthy individuals. A total of 1 145 genes showed significant differences (q-value<0.05)
in mRNA expression levels between the two groups: 700 and 445 genes were over and under-
expressed, respectively, in the RARS samples (S1 Fig and S4 Table). The most over-expressed
gene in RARS was GDF15 (p-value< 0.0001; R fold = 20.27). In addition, genes associated
with iron and mitochondrial metabolism represented the largest function group of genes in-
volved: 38% (266 molecules) of the over-expressed genes were identified in this study. Of these
genes, 106 were related to mitochondria function, 13 were related to iron binding, including
CYBRD1, STEAP3 and ACO1, while 11 were involved in the heme biosynthetic process, six of
which (ALAD,HMBS, UROS, UROD, CPOX, PPOX) had a direct role in heme formation. In
addition, ABCB6, whose function is to move coproporphyrinogen III from the cytoplasm into
the mitochondria during heme biosynthesis, was over-expressed in RARS patients. Nine genes
were related to cellular iron ion homeostasis, of which TF, TFR2, TFRC, FXN, SLC25A37 and
SCL25A38 were up-regulated in RARS patients (Table 1).
To determine whether the genes involved in mitochondrial metabolism were exclusive to
the RARS expression profile, this group of patients was compared with other low-risk MDS
cases (RCUD group). The comparative analysis of the gene expression profile of both groups
identified a set of 192 differentially expressed genes: 128 genes were up-regulated in RARS pa-
tients while 64 were down-regulated (S2 Fig and S5 Table). Interestingly, 33% (42 genes) of the
over-expressed genes were related to iron and mitochondrial metabolism as inferred from the
functional enrichment analyses. 33 genes were related to mitochondria, five were associated
with iron binding and eight were involved in heme formation. Thus, ALAD, HMBS, UROS,
UROD, CPOX and PPOX were over-expressed in RARS patients with respect to the other low-
risk MDS (Table 2).
Validation of the RARS expression signature with independent datasets. In order to
validate the expression signatures found in our unfractionated cohort of MDS samples, a com-
parison between the present studies and an independent cohort of MDS patients where CD34
+ cells were isolated (published by Pellagatti et al. 2010) [35] was carried out. Odds ratio was
used to measure how strongly is the overlapping of the altered genes in both analysis. Analys-
ing the Pellagatti et al. dataset (GSE19429), a total of 5 840 genes showed significant differences
(FDR 0.05) in mRNA expression levels between CD34+ cell from RARS patients (using only
MDS-RS samples with normal karyotype) and their control group: 3 697 and 2 143 genes were
over and under-expressed, respectively, in the RARS samples. This signature had a significant
overlap of 457 genes with our signature for the same RARS vs controls comparison (only con-
sidering the up-regulated genes); which corresponds to an odds ratio for this comparison of
7.14 (Lower CI 95% = 8.38).
Further analysis of the Pellagatti data (34) for the CD34+ differential expression between
RARS and RCUD groups identified a set of 404 differentially expressed genes (FDR 0.05):
284 genes were up-regulated in RARS patients while 120 were down-regulated. A very signifi-
cant overlap was also observed between this up-regulated gene set and the set of 128 genes that
we discovered up-regulated in our RARS patients versus the RCUD group (Odds ratio = 31.83;
Lower CI 95% = 21.51).
DNA Variants in Refractory Anemia with Ring Sideroblasts
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A targeted genome capture and next-generation sequencing strategy
identifies gene variants in MDS with ring sideroblasts
In order to identify any gene variants in MDS-RS, a capture and sequence approach was done
on 93 genes from a group of 6 MDS with ring sideroblasts using a custom NimbleGen array
was carried out: 39 of the gene targets were related to iron and mitochondrial metabolism (S6
Table). The enrichment assay followed by NGS detected a total of 8 230 variants in all patients
analyzed (median 1 367 variants per sample, range 1 078–1 672). All putative variants were
Table 1. Most representative deregulated cellular functions in RARS patients respect to the control group.
Fuction Number of
genes
p Value Over-expressed genes
MITOCHONDRION 106 5,70658E-
46
Membrane and Mitochondrion 32 0,00000000 VDAC3, NDUFV3, SLC25A15, SLC25A36, SLC25A38, ATP7B, BCS1L, C18orf55,
HAX1, TIMM50, NDUFB6, APOO, HTRA2, CYB5A, MTX2, NDUFS2, TMEM14C,
ABCB6, SLC25A37, C3orf1, CCDC90A, ABCB10, STOML2, STXBP1, HK1, NDUFS4,
MRPS17, PPOX, TIMM44, MAOA, SLC25A20, CLIC4
Mitochondrial inner membrane 23 0,00000000 VDAC3, CHCHD3, NDUFV3, SLC25A15, SLC25A36, SLC25A38, DCI, NME4, BCS1L,
NDUFB6, COX15, APOOL, NDUFS2, SLC25A37, SHMT2, HSPD1, FDXR, ABCB10,
GCDH, STOML2, GCAT, NDUFS4, SLC25A20
Cytoplasm and Mitochondrion 21 0,00000002 LONP1, GART, PPP2CA, ATP7B, CAPRIN2, APOO, CYB5A, TP53, DARS2, TXN2,
HSPD1, HEBP1, STOML2, SOD1, STXBP1, ISOC2, THG1L, AIFM1, OAT, CLIC4,
HMBS
Mitochondrial matrix 16 0,00000003 DNAJA3, DCI, ETFA, COQ3, ACAT1, MIPEP, PCCB, DARS2, HSPD1, FDXR, FXN,
GCDH, SOD1, HSPE1, TIMM44, OAT
Nucleus and Mitochondrion 14 0,00000128 GART, PPP2CA, C14orf156, HAX1, TIMM50, REXO2, HTRA2, TP53, APEX2, BRD8,
TSFM, SOD1, ISOC2, AIFM1
Nucleolus and Mitochondrion 4 0,00077681 GART, TP53, TXN2, BRD8
PROTEIN BINDING 25 0,00000000 VDAC3, CHCHD3, LONP1, DLAT, GART, MRPS9, PPP2CA, ATP7B, PMAIP1,
TIMM50, ACAT1, TUFM, SHMT2, FDXR, FXN, GCDH, STXBP1, ISOC2, TIMM44,
ATP5B, ARG2, MAOA, AIFM1, OAT, CLIC4
NUCLEOTIDE BINDING 17 0,00000000 VDAC3, LONP1, GART, ATP7B, NME4, C14orf156, BCS1L, TRAP1, DARS2, TUFM,
ABCB6, HSPD1, ABCB10, MRPL39, HK1, TIMM44, ATP5B
ATP BINDING 15 0,00000006 LONP1, GART, ATP7B, NME4, BCS1L, TRAP1, TP53, DARS2, ABCB6, HSPD1,
ABCB10, HSPE1, HK1, TIMM44, ATP5B
TRANSPORT 15 0,00000027 NDUFV3, SLC25A15, SLC25A36, SLC25A38, ETFA, NDUFB6, CYB5A, NDUFS2,
TXN2, ABCB6, FDXR, ABCB10, NDUFS4, MRPS17, SLC25A20
IRON ION BINDING 13 0,00003287 PPAT, RRM2, PPP2CA, LIAS, DOHH, RFESD, CYBRD1, MIPEP, ACO1, SLC11A2,
NDUFS2, SLC25A37, STEAP3
ELECTRON CARRIER
ACTIVITY
13 0,00028086 ETFA, RFESD, NDUFS2, TXN2, TSTA3, FDXR, STEAP3, GCDH, TXNL3, PPOX,
MAOA, AIFM1, SUOX
HEME BIOSYNTHETIC
PROCESS
11 0,00000001 ALAD, UROS, FXN, PPOX, CPOX, UROD, HMBS, COX15, EPRS, BLVRB, ABCB6
ELECTRON TRANSPORT
CHAIN
11 0,00000514 NDUFV3, FADS2, ETFA, CYBRD1, NDUFB6, CYB5A, TXNL1, NDUFS2, TXN2, FDXR,
NDUFS4
CELLULAR IRON ION
HOMEOSTASIS
9 0,00000053 MYC, TF, ABCB6, FXN, TFR2, SOD1, TFRC, SLC25A37, SLC25A38
HYDROLASE ACTIVITY 8 0,00009485 MTHFD2, PPP2CA, ATP7B, REXO2, HINT2, THEM2, ATP5B, ARG2
METABOLIC PROCESS 8 0,00017248 DLAT, C5orf33, DCI, LIAS, ATP7B, COQ3, ACAT1, ISOC2
OXIDOREDUCTASE ACTIVITY 8 0,00062130 RFESD, TSTA3, FDXR, STEAP3, PPOX, MAOA, AIFM1, SUOX
ACYLTRANSFERASE
ACTIVITY
6 0,04443590 DLAT, ESCO2, KS, NAT13, GCAT, TGM2
ION TRANSPORT 5 0,00039908 ATP7B, TF, SLC25A37, ATP5B, CLIC4
doi:10.1371/journal.pone.0126555.t001
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first compared with published single nucleotide polymorphism (SNP) data from dbSNP130.
The 2 217 known SNPs (56%) were discarded along with the new variants found at non-coding
regions (85%) and, finally, those that did not give rise to an amino-acid change in their protein
sequence (58%)
As a result, a missense variation was detected in the ALAD gene in one case with ring sidero-
blasts (Chr9: 116,152,735); therefore the incidence of this variation, and known SNPs, were ex-
amined, by Sanger sequencing, in a larger cohort of 100 MDS patients with ring sideroblasts. In
addition, conventional mutational analysis as alternative approach was also performed for the
SLC25A37 and SLC25A38 genes.
RARS patients present a frequent haplotype in exon 6 and a new variant
in exon 7 of the ALAD gene
Two known polymorphisms have been reported in exon 6 of the ALAD gene: rs8177807
(T10728C) and rs2228083 (C10679T). The SNPs were located at positions Chr9: 116,152,891
and Chr9: 116,152,940, respectively, 49 base pairs from each other. The study revealed two pos-
sible haplotypes for these variants: “common haplotype” (T10728 and C10679) and “variant
haplotype” (C10728 and T10679). Interestingly, the “variant haplotype” was present in 12 of
100 MDS with ring sideroblasts (12%), while it was only found in 5 of 100 controls and RCUD
patients (5%) (p = 0.07).
In addition, exon 7 of the ALAD gene was analyzed in a larger cohort of MDS with ring side-
roblasts (n = 100) and the change previously identified by the capture and sequence approach
was confirmed by conventional sequencing (Fig 1A). The positively charged arginine residue
(R174) was replaced by an uncharged cysteine residue (Fig 1B). The three-dimensional struc-
ture showed that R174 residue is completely buried into the monomeric structure (Fig 2) and
the protein was predicted to be potentially damaging.
Furthermore, the variant was found in the CD3+ cells of PB from the same patient suggest-
ing the presence of a germ line mutation. The variant was not found in any of the control sam-
ples or in those analysed from RCUD patients.
Table 2. Most representative deregulated cellular functions in RARS patients respect to the RCUD group.
Fuction Number of
genes
p Value Over-expressed genes
MITOCHONDRION 33 0,000000
Integral to membrane 15 0,047316 GBGT1, ST6GALNAC4, SLC25A38, AADACL1, CYBRD1, TSPAN17, RHBDD1, APOO,
TMEM14C, KCNH2, MS4A7, PPAPDC1A, STEAP3, ABCB10, AC079061.8
Cytoplasm and
mitochondrion
7 0,000042 ATP7B, CAPRIN2, APOO, HSPD1, HEBP1, ISOC2, HMBS
Membrane 6 0,002383 SLC25A38, ATP7B, APOO, TMEM14C, ABCB10, PPOX
Mitochondrial inner
membrane
4 0,009138 SLC25A38, NME4, HSPD1, ABCB10
HEME BIOSYNTHETIC
PROCESS
8 0,000000 ALAD, UROS, PPOX, CPOX, UROD, HMBS, EPRS, BLVRB
NUCLEOTIDE BINDING 6 0,000019 ATP7B, NME4, C14orf156, TRAP1, HSPD1, ABCB10
ATP BINDING 5 0,000078 ATP7B, NME4, TRAP1, HSPD1, ABCB10
PROTEIN BINDING 5 0,002258 MRPS9, ATP7B, ACAT1, ISOC2, ARG2
IRON ION BINDING 5 0,000516 PPAT, PIR, RFESD, CYBRD1, STEAP3
doi:10.1371/journal.pone.0126555.t002
DNA Variants in Refractory Anemia with Ring Sideroblasts
PLOS ONE | DOI:10.1371/journal.pone.0126555 May 8, 2015 7 / 16
SLC25A37 (Mitoferrin-1) is un-mutated in acquired RARS
SLC25A37, that encodes a mitochondrial iron transporter that specifically mediates iron uptake
in developing erythroid cells, was over-expressed in RARS patients (R Fold = 1.70). Therefore,
a complete sequence analysis of the SLC25A37 gene was performed in the group of 50 patients
MDS with ring sideroblasts: 62% of all the cases analyzed had at least one known polymor-
phism in their sequence. Specifically, the polymorphisms were located in exons 2 and 4 of
SLC25A37 with 6% of the patients having the rs1047384 polymorphism (exon 4). The majority
of polymorphisms (56%) were in exon 2; furthermore, 38%, 14% and 4% of cases exhibited
one, two or three polymorphisms in this exon, respectively (S3 Fig). All polymorphisms were
homozygous. No new variations were observed in the SLC25A37 gene in the patients with
ring sideroblasts.
SLC25A38 showed a new mutation in one patient with RCUD
SCL25A38, recently described as a mutated gene in congenital sideroblastic anemia, was found
to be over-expressed in RARS patients in our study (R Fold = 1.78). We further analyzed this
gene by sequencing in the group of low-risk MDS patients (n = 175). A new missense mutation
was observed in the BM from one of the RCUD patients. The mutation, in exon 4, was located
at position Chr3: 39,432,957 and resulted in the amino-acid change of valine for alanine
(V97A) (Fig 3A–3B).
In addition, three known polymorphisms (rs1995236, rs870843 and rs9877539) were ob-
served in the SCL25A38 sequence in the group of low-risk MDS. They were located close to the
coding sequence for 4, 6 and 7 exons. Interestingly, both rs1995236 and rs9877539 polymor-
phisms were homozygous for the less common variants in the population (100% and 97.6% of
all the cases with these variations, respectively) (S7 Table).
Fig 1. Variation in the ALAD gene in a RARS case. (A) Newmissense variation in the ALAD gene in the
BM of one RARS patient found by massive sequencing. The variation is heterozygous and is located at Chr9:
116,152,735 position in exon 7. (B) Protein sequences from wild-type and RARS patient. Amino-acid change
in the protein sequence of ALAD in a RARS patient. Arginine (R174) is replaced by cysteine y the mutant
protein. (RARS: refractory anemia with ring sideroblasts)
doi:10.1371/journal.pone.0126555.g001
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Recurrent SF3B1 and SRSF2Mutations in low-risk MDS patients
SF3B1, recently described as a mutated gene in a high proportion of MDS patients with ring
sideroblasts, was analyzed in the same cohort of patients with MDS-RS (n = 100). SF3B1 was
mutated in 82 of 100 cases with ring sideroblasts (82%). Exon 15 was more frequently mutated
(47%) than exon 14 (32%). The mutations in exon 15 were located in the same codon (700)
while those in exon 14 were located in four codons: 622 (7%), 625 (1%), 662 (12%) and 666
(12%). All patients had a single mutation in the gene, except for three cases (3%), which had
two changes. One of them showed the mutations in the same exon (codons 662 and 666) while
the mutations in the other two patients were located in different exons (codons 666 and 700).
However, the clinical characteristics of these patients did not differ from those with a
single mutation.
No relationships between the presence of polymorphisms in SCL25A37 or SLC25A38 and
SF3B1mutations were found. The case with ALAD variation showed a mutation in the SF3B1
gene (exon 14, codon 662).
In addition, a mutational study of SF3B1 and SRSF2 in all RCUD patients with available ex-
pression profile information was carried out. 30% of the cases showed mutations in SF3B1,
10% carried variations in SRSF2 and 60% showed non-mutations in any of the genes analyzed.
Fig 2. Three-dimensional structure of the ALAD protein.Monomeric structure of the ALAD protein. The
red color indicates the position of the arginine 174. The amino acid is completely buried into the monomeric
structure of the ALAD protein.
doi:10.1371/journal.pone.0126555.g002
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The mutations detected in RCUD were located in hot-spots previously described by other
groups. Specifically, they were observed in codons 622, 625, 662, 666 and 700 in the SF3B1
gene and codon 95 in SRSF2.
Gene expression profile showed significant differences between
mutated patients and non-mutated cases
A supervised analysis of GEP between mutated low-risk MDS cases (RARS and RCUD) and
non-mutated low-risk MDS patients was carried out. Herein, GDF15 was the most up-regulat-
ed gene in low-risk MDS patients with mutation in spliceosome-related genes. ALAD,
SLC25A37, SLC11A2, PCK2,MRPS9, AIFM2 and HK1, all of them involved in iron and mito-
chondrial metabolism, were also over-expressed and were included in the Top200 more differ-
entially expressed genes (S8 Table). In addition, a functional study with this gene Top200 gene
set showed that cell cycle (Benjamini-Hochberg value< 0.0003) and mitosis (Benjamini-Hoch-
berg value< 0.005) were the most frequently deregulated molecular functions, involving 24
and 21 differentially expressed genes, respectively.
A supervised analysis between the gene expression levels of SF3B1mutations patients and
non-mutated MDS-RS cases was carried out. An over-expressed gene-signature of 71 genes
was identified between both sub-groups (S9 Table). Interestingly, GDF15 was overexpressed in
patients showing SF3B1mutations. In addition, other genes such as PPP2R5B, PPP1R16A and
DDIT4L, related to SF3B1 and GDF15, were up-regulated in the mutated group. A functional
analysis with this gene set showed two deregulated pathways: porphyrin biosynthesis and
heme biosynthesis (p< 0.001). ALAS2, PPOX and UROD, all of them involved in heme forma-
tion, were also over-expressed in the mutated patients.
Fig 3. SLC25A38mutation in a RCUD patient. (A) Newmissense mutation in exon 4 of a RCUD patient detected in BM by Sanger sequencing. The
mutation is heterozygous and is located at the Chr3: 39,432,957 position. (B) Amino-acid change in the protein sequence of SLC25A38 in the RCUD patient.
Valine 97 is replaced by alanine in the mutant protein. (RCUD: refractory cytopenia with unilineage dysplasia).
doi:10.1371/journal.pone.0126555.g003
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Discussion
The integrative analysis of the massive gene analysis has provided new insights in the knowl-
edge of the pathogenesis of MDS [27]. In the present study, an over-expression of iron and mi-
tochondrial metabolism related genes was observed in patients with RARS. Therefore a custom
sequence capture array was designed in order to identify genes that could play a role in the
pathogenesis of MDS with ring sideroblasts.
The use of unfractionated compared to fractionated cells in this type of expression or se-
quencing study has become a matter of debate in recent years. The approach taken in the pres-
ent study is supported by previous studies that have been able to identify biological and
prognostic characteristics in MDS and AML by studying the gene expression profile and the
use of unfractionated mononuclear cells [27,36,37]. Furthermore, the results of the present
study are supported by previous reports in CD34+ cells [8] due to a significant overlap between
both analysis. The use of CD34+ cells is of great scientific value while the analysis of unfractio-
nated samples could allow the identification of the interaction between the different cell types.
In this respect, the present study has suggested that the erythroid lineage displays a robust gene
expression signature that allows the identification from the global set of mononuclear cells.
Interestingly, the most significant functional category from the gene expression signature
was iron and mitochondrial metabolism. This category had the highest proportion of genes
over-expressed in RARS patients when compared to the controls or the RCUD group, repre-
senting 38% and 33% of all over-expressed genes, respectively. Of note, six key enzymes in the
heme biosynthesis pathway showed increased expression, some members of this pathway are
also over-expressed in CD34+ cells of RARS patients [8]. In addition to the enzymes that cata-
lyze heme formation, our study highlighted the over-expression of the ABCB6 gene in RARS
patients. This molecule is ideally located in the outer membrane, where it can move copropor-
phyrinogen III from the cytoplasm into the mitochondrion using ATP hydrolysis as the source
of energy [7,38]. The deregulation of ABCB6 expression may contribute to the impaired heme
biosynthesis found in MDS with ring sideroblasts.
The ALAD gene encodes a cytosolic enzyme that catalyses the condensation of two mole-
cules of d-aminolevulinic acid (ALA) to form porphobilinogen (PBG) in the second step of the
heme biosynthetic pathway [39]. Our analysis of the ALAD gene identified two polymorphisms
in exon 6 located 49 bases from each other and, interestingly, the presence of one of them was
always determined by the presence of the other one. The occurrence of both polymorphisms
(“variant haplotype”) was more frequent in MDS with ring sideroblasts (12%) than in members
of the other groups analyzed (5%). Therefore, our study showed a trend to an association of the
variant haplotype with the ring sideroblasts. The presence of haplotypes has been linked to the
deregulation of the genes in different hematological malignances, such as chronic lymphocytic
leukemia and acute lymphoblastic leukemia [40,41]. Thus, these findings could be related to
the deregulation of the ALAD gene and consequently to the abnormal iron and mitochondrial
metabolism in MDS with ring sideroblasts.
The capture and sequencing study identified a non-described sequence change in the ALAD
gene in one RARS patient showing a SF3B1mutation; the ALAD gene was also up-regulated in
the gene expression studies. The variants of this gene were also found in the CD3+ population
in the PB. In addition, the variant led to amino-acid change in the ALAD protein. Therefore
this variant could have a possible role in the predisposition to disease (as a first event) as well
as contributing to the pathogenesis of RARS where SF3B1mutations are the trigger cause.
In addition, we have identified a new missense mutation in exon 4 of the SCL25A38 gene in
one RCUD patient. Thus, the mutation led to the 97V>A amino-acid change in the protein se-
quence. SLC25A38 gene has been previously linked to congenital sideroblastic anemia [14].
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These findings would indicate that mutations in the SLC25A38 gene might be associated to the
low-risk MDS.
SLC25A37 is a member of the mitochondrial solute carrier family. Some authors have
shown that SLC25A37 contributes to mitochondrial iron acquisition in mammalian cells, since
decreases in SLC25A37 severely reduce mitochondrial iron-consuming processes, such as
Heme and Fe-S cluster synthesis. In fact, mitochondrial iron transport is reduced by more than
90% in cells silenced for SLC25A37, suggesting that SLC25A37 is a major contributor to mito-
chondrial iron acquisition [42,4]. Our results showed up-regulation of SLC25A37 in RARS pa-
tients with respect to the control group. These findings led us to hypothesize that this over-
expression could be responsible of iron accumulation. For these reasons, we sought out to de-
termine whether MDS with ring sideroblasts cases were characterized by SLC25A37 somatic
mutations. No mutations were found for this gene in cases with ring sideroblasts. Therefore,
other mechanisms give rise to the over-expression of the SLC25A37 gene in RARS patients. In
addition, it should be noted that no relationships between the presence of polymorphisms in
SCL25A37 or SLC25A38 and SF3B1mutations were found.
The GEP from the BM of SF3B1mutated patients was compared to that from the BM of
non-mutated individuals. 71 genes showed over-expression in mRNA levels in mutated cases.
Interestingly, two pathways observed in the functional analysis were related to mitochondrial
metabolism. GDF15, a cytokine from the TGFβ family, was one of the most highly differentially
expressed gene. GDF15 is expressed at high levels in patients with ineffective erythropoiesis. In
contrast to the low levels of GDF15 expressed during normal erythropoiesis, ineffective eryth-
ropoiesis causes high-level expression of GDF15 [43]. In addition, it has been suggested that
over-expression of GDF15 in patients with RARS might be involved in the systemic iron over-
load by suppressing hepcidin secretion [43,44], being sensitive to iron depletion and this re-
sponse is specifically antagonized by the reprovision of iron [45]. Therefore, the GDF15 over-
expression could be related to the presence of mutations in SF3B1 gene, and therefore, to a
higher percentage of ring sideroblasts previously described [17]. These findings also suggest
that the up-regulation of ALAS2, PPOX and UROD, all of them involved in heme formation,
could be related to the presence of SF3B1mutations. Furthermore, the comparison between
the GEP of mutated low-risk MDS patients and non-mutated cases showed the cell cycle and
mitosis as the most frequently deregulated pathways. This would support the hypothesis that a
mutation in spliceosome-related genes could be the trigger cause, and support the presence of a
second event for the deregulation of iron and mitochondrial metabolism.
In summary, our integrated expression and sequencing approaches has identified both the
deregulation of genes involved in iron and mitochondrial metabolism and a new variant in the
ALAD gene. Both potential mechanisms provide new insights into the pathogenesis of MDS
with ring sideroblasts and, specifically, in patients with SF3B1mutations.
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